WMT AG

Biotechnology - Therapeutics and Diagnostics

proteona.png

Immunotherapy I small molecules

WMT develops small molecules to treat late stage solid cancers. We target the so-called Warburg metabolism, i.e. the high rate of glycolysis and lactate production that is adopted by late stage tumours. By applying our anti Warburg Warheads (AWWs) we dim down this specific form of cancer metabolism, thereby lowering the lactate in the tumour microenvironment. In result we achieve an inhibition of tumour growth as such as well as re-stimulation of the immune system against the solid tumour. We are at preclinical stage but we have proprietary compounds that demonstrate these effects in vivo